miRNA-195 expression in the tumor tissues of female Brazilian breast cancer patients with operable disease

• Autor(a) principal: Sales, Alexandre Cesar Vieira de
• Data de Publicação: 2021
• Outros Autores: Silva, Isaura Isabelle Fonseca Gomes da, Leite, Matheus Carvalho Brito, Coutinho, Leandro de Lima, Reis, Renata Bezerra de Albuquerque Cavalcante, Martins, Danyelly Bruneska Gondin, Lima Filho, José Luiz de, Souto, Fabrício Oliveira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Clinics
• DOI: 10.6061/clinics/2021/e2142
• Texto Completo: https://www.revistas.usp.br/clinics/article/view/191717
• topic: miRNA-195; Breast Cancer; Biomarker; Tumor Tissue; Neoadjuvant Chemotherapy

OBJECTIVE: This study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers. METHODS: Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to evaluate the miRNA-195 expression in tumor tissues from a cohort of female breast cancer patients undergoing NAC. This expression was then correlated with the occurrence of several distinct breast cancer molecular subtypes and other clinicopathological variables. RESULTS: A total of 55 patients were included in this study, 28 (50.9%) of whom were treated using NAC. Tumor miRNA-195 expression was suppressed in breast cancer patients, regardless of their exposure to systemic treatments, histological grade, size, nodal status, and tumor-node-metastasis (TNM) staging. This was more pronounced in luminal and triple-negative patients, and patient’s response to NAC was correlated with an increase in miRNA-195 expression. CONCLUSION: miRNA-195 is downregulated in the tumor tissues of Brazilian breast cancer patients regardless of NAC exposure; this reinforces its role as a tumor suppressor and a potential biomarker for chemotherapy response.